文献速递系统性红斑狼疮其他结缔组织病

免疫介导炎症性疾病心包疾病的评估与治疗

Evaluation and treatment of pericardial disease in immune-mediated inflammatory diseases.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本文综述免疫介导炎症性疾病(IMID)相关心包疾病的评估与治疗,指出心包疾病在IMID患者中常见,尤其在SLE中。诊断依赖通用诊断标准、炎症生物标志物及无创多模态成像;初始治疗与特发性心包炎重叠(NSAIDs和秋水仙碱),同时治疗基础IMID。

要点

  • 心包疾病在IMID患者中常见,尤其是SLE,可表现为无症状心包积液或急性和复发性心包炎。
  • 诊断依赖通用诊断标准,辅以炎症生物标志物和无创多模态成像。
  • 初始治疗与特发性心包炎重叠(NSAIDs和秋水仙碱),同时治疗基础IMID。

核心结论

  • IMID相关心包疾病常见,尤其在SLE中,可表现为无症状心包积液或急性和复发性心包炎,有时导致心脏压塞和缩窄性心包炎等并发症。
  • IMID中心包炎病理生理可能与基础免疫失调相关。
  • IMID相关心包炎诊断依赖通用诊断标准,辅以炎症生物标志物和无创多模态成像。

研究设计与样本

  • 本文为综述,评估和治疗免疫介导炎症性疾病(IMID)相关心包疾病。

主要发现

  • 心包疾病在IMID患者中常见,尤其是SLE。
  • 心包疾病可表现为无症状心包积液或急性和复发性心包炎,有时导致心脏压塞和缩窄性心包炎。
  • IMID中心包炎病理生理可能与基础免疫失调相关。

关键数值与推荐

  • IMID相关心包炎诊断依赖通用诊断标准,辅以炎症生物标志物和无创多模态成像。
  • 初始治疗与特发性心包炎重叠(NSAIDs和秋水仙碱),同时治疗基础IMID。
  • 对一线治疗反应不佳者使用糖皮质激素。
  • 免疫抑制治疗的使用由基础IMID和心包以外的全身器官受累驱动。

临床怎么用

  • IMID相关心包炎初始治疗与特发性心包炎重叠(NSAIDs和秋水仙碱),同时治疗基础IMID。
  • 对一线治疗反应不佳者使用糖皮质激素。
  • 免疫抑制治疗的使用由基础IMID和心包以外的全身器官受累驱动。
  • 心脏科、放射科、内科和风湿科之间的多学科协作至关重要,以根据每位IMID患者的个体特征制定适当、共同的治疗计划。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pericardial disease is common in patients with immune-mediated inflammatory diseases (IMIDs), especially in SLE. Pericardial disease may present as an asymptomatic pericardial effusion or acute and recurrent pericarditis, and may sometimes lead to complications (cardiac tamponade and constrictive pericarditis). Pathophysiology of pericarditis in IMIDs is likely related to the underlying immune dysregulation. Diagnosis of IMID-related pericarditis relies on general diagnostic criteria, supported by inflammatory biomarkers and non-invasive multimodality imaging. Initial management of IMID-related pericarditis overlaps with idiopathic pericarditis (NSAIDs and colchicine) together with treatment of the underlying IMID. Glucocorticoids are used in cases of poor response to first-line treatments. The use of immunosuppressive therapies is driven by the underlying IMID and systemic organ involvement beyond the pericardium. Multi-disciplinary care collaboration between cardiologists, radiologists, internists and rheumatologists is pivotal to develop an appropriate, common treatment plan based on the individual features of each patient with IMIDs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bonaventura A, Garshick M, Malandrino D, et al. Evaluation and treatment of pericardial disease in immune-mediated inflammatory diseases. Rheumatology (Oxford). 2026. PMID: 42225844. doi:10.1093/rheumatology/keag283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。